Member Info for GloriaMarket

This link https://research.cmft.nhs.uk/news-events/manchester-leads-implementation-of-lifesaving-genetic-bedside-stroke-test

allowed me to put myself in the shoes of the NHS and I concluded that the manchester clinicians PREFER GDR's test kit to lab testing..

"Professor Bill Newman, Consultant in Genomic Medicine at MFT and Professor of Translational Genomic Medicine at The University of Manchester who led the project said: “Strokes affect more than 6,000 people in Greater Manchester each year and those affected are at increased risk of further severe strokes in the following hours, days and weeks.

“This is clearly a particularly worrying time for patients and their families; therefore, it is vital we use new approaches to ensure that patients get onto the right treatment as quickly as possible.” This in turn will save the NHS 160 million per year.

"When you factor in the potential improvements in patient’s quality of life, the model estimates that the potential value of the test to the NHS is over £160 million each year.”"

2. NICE recommends lab testing FIRST and ONLY when a lab test is not available can they use GDRs kit.

So how important is the NICE advice. CLearly Prof Newman doesn't agree with it, he wants to use GDR's kit. Will his NHS manager give him and his colleagues the budget to do so? And will the NHS managers of other hospital procure the kit and allow clinicians to use it, even if lab testing is available?

As I see it GDR needs to convince NHS managers that their kit, even though its more expensive will save time and money above lab testing. However, again I fear GDR got their pricing strategy WRONG . They needed to undercut the competition ie lab testing. I'd love to have been a fly on the wall when GDR came up with the price per test of £100 , knowing that a lab test costs £40. I've been in such procurement meetings and generally the cheapest solution is opted for by everyone involved. Had GDR been cheapest solution the kit would be the preferred choice and not lab testing. YEt as it stands, Mr Cheek cannot project sales because the kit is the second choice of the NHS. This is hugely damaging in terms of investor interest. Only time will tell how much sales revenue GDR kit generates as NHS' second choice.

GDR priced their test incorrectly imo and they have a track record of pricing themselves out of a huge market.

Good article. Its clear the clinicians at manachester prefer GDRs CYP2C19 gene kit test. NICE does not. Yet both lab testing and CYP2C19 gene kit will save the NHS millions, the only difference bewteen each lab and GDRs CYP2C19 gene kit test is approximately £50.

"Cheek now needs to start delivering announcements of sales agreements. Can he do it?"

Good question! Lab testing is the preferred choice so how much sales revenue does Mr Cheek expect?

But perhaps the SP will not care. I beginning to regret selling. Lol. Time will tell though!

" Even a sales forecast would be a milestone."

trading update required.

"However deramping a share is designed to suppress the share price as is continuing to post negative comments in a share that you are no longer invested in."

ramping or deramping on LSE does not affect the SP regardless of the ego's of some of its posters.

"However deramping a share is designed to suppress the share price as is continuing to post negative comments in a share that you are no longer invested in."

deramping on LSE does not affect the SP regardless of the ego's of some of its posters.

"The spread of misinformation LSE states that it does not allow ... yet they allow it every day on virtually every company that receives good news."

ramping and deramping alike. I've noticed that there are far more outrageous claims by rampers than derampers. Probably 80% of posts are positive ramps, 10% questions and 10% completely negative deramps. The reason is because most people who comment are invested so they are very unlikely to criticise their own investment. NB I've sold due to unanswered questions by the RNS and NICe announcement.

"£5m cash in the bank"

correct

"and a revenue of at least £8.5m a year starting in August/September 2024"

trading update needed.

I've taken profit. GLA.

Mr Arch-stanton,

Copy-paste makes a huge difference.

"Whilst positioned primarily for enabling near-patient testing, the Genedrive® System is also suitable for traditional laboratory testing paradigms as a more affordable alternative to laboratory platforms where sample throughput requirements do not necessitate high-scale batch processing."

Yes ,this make more sense but doens't answer any of my questions, it is the reason for my questions. We know nothing about the current status of lab testing or its intent to ramp up8 its capacity. The labs are GDRs direct competitor and NHS wants hospitals to use them. My questions, and many more have not been answered by GDR. As I see it GDR sales team need to promote GDRs product so that clinicians choose it, over lab testing. The RNS states that the clinicians want quick results and imo would choose GDR every time, the NHS managers however want to keep costs down and NICE RNS has essentially forced clinicians to first check whether lab testing is available BEFORE they can choose GDR.

Does the NICE announcement mean that EVERY hospital in the NHS will be required to buy a GDR machine regardless of current lab testing capacity? Mr Cheek needs to tell us imo.

Mr Cheek needs to provide a sales prediction now full recommendation has been given.

My questions are not deramps, only sales and a trading update will ultimately answer these questions, as Mr Emeraldcarrot also put it.

" GDRs test is suitable for lab testing anyway"

THis makes no sense whatsoever. Makes you sound like an AI bot.

" Expect positive trading updates going forward."

This is CRUCIAL for GDRs survival imo. The lab testing is the elephant in the room, we don't know when "lab testing is unavailable" or what the status of the lab testing is. Do labs even exist now that test for the gene? How long does it take for a hospital to find out that lab testing is unavailable? Do the hospitals even know who to ask whether lab testing is available?

We only know that NICE wants hospitals to choose lab testing first. Really frustrating for all concerned.

MR Sharedealer, looks like you were right to buy at those prices. GLA.

" Does the patient get a bed in the hospital and wait??????????????!"

No they are given Clopidogrel and sent on their way. Clopidogrel is metabolised into its active form by an enzyme, yet people with genetic variations in the CYP2C19 gene which encodes this important enzyme means Clobidogrel is not metabolised into it's active form and as such the drug is far less effective. Once the genetic test is completed the doctors will know where an alternative to Clopidogrel should be prescribed. For patients with the gene variation , taking medicine that works is very important whether or not wiating a day or 2 will make much of a difference I don't know. Ask a doctor. DrNash are you a real doctor of medicine or a LSE "doctor" ?

The current sp suggests that NICE recommendation is priced in. I believe this because sp started to rise to from 1.6p to 2.2p and only rocketted to 3.5p+ based on the suprise RNS regarding the breakthrough program. But it all depends on the RNS tomorrow and whether GDR and investors will be given more clarity regarding NHS sales figures.

"1.3 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19

genotype testing when laboratory-based testing is not available."

People here have stated that lab testing is currently not available. How would they know?

Rampers vs derampers.... Tomorrow, the RNS of the century will decide who wins (as decided by the SP at close of business tomorrow - higher or lower than today).

rampers argue the sp is underpriced by 1-4p (should be 5-8p).

derampers argue the current sp is overpriced by 1-1.5p .